Literature DB >> 34250294

The advances in dealing with the safety of medicated drugs in pregnancy.

Atsuko Murashima1,2, Naho Yakuwa1, Sachi Koinuma1, Chiaki Uno1,3, Chinatsu Takai1, Izumi Fujioka1, Mikako Goto1, Naoki Ito1,4, Omi Watanabe1, Akimasa Yamatani1,3.   

Abstract

The Japan Drug Information Institute in Pregnancy (JDIIP) was established with the aims of providing information on drug safety to women who are worried about drug use during pregnancy and creating evidence through epidemiological studies based on counseling cases. Since being established, JDIIP has made many contributions to the wellness of mothers and children by promoting the proper use of drugs during pregnancy. A network consisting of Core hospitals in 47 prefectures plays an important role in providing information for women living anywhere in Japan. Because cases of exposure to drugs whose safety we want to analyze are usually rare, networks of domestic and foreign teratology information services are necessary in order to produce high-quality evidence. JDIIP has been contributing to the education of pharmacists and doctors and to the creation of clinical practice guidelines in various medical societies by using keywords such as "pregnancy" and "medication". Future issues include creating an environment that is easily accessible for those seeking consultation, building a mechanism that makes it easy to create a basis for safety, and aiming for the continuing development of the organization. 2021, National Center for Global Health and Medicine.

Entities:  

Keywords:  counseling; drug safety; epidemiological study; pregnancy

Year:  2021        PMID: 34250294      PMCID: PMC8239373          DOI: 10.35772/ghm.2020.01120

Source DB:  PubMed          Journal:  Glob Health Med        ISSN: 2434-9186


  6 in total

1.  Perception of pregnant Japanese women regarding the teratogenic risk of medication exposure during pregnancy and the effect of counseling through the Japan drug information institute in pregnancy.

Authors:  Naho Yakuwa; Ken Nakajima; Sachi Koinuma; Mikako Goto; Tomo Suzuki; Naoki Ito; Omi Watanabe; Atsuko Murashima
Journal:  Reprod Toxicol       Date:  2018-06-06       Impact factor: 3.143

Review 2.  Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women.

Authors:  Toshihiro Tanaka; Ken Nakajima; Atsuko Murashima; Facundo Garcia-Bournissen; Gideon Koren; Shinya Ito
Journal:  CMAJ       Date:  2009-06-15       Impact factor: 8.262

3.  Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.

Authors:  Kayoko Hishinuma; Ritsuko Yamane; Ikuko Yokoo; Takahide Arimoto; Kunihiko Takahashi; Mikako Goto; Yoshiyuki Saito; Ken Nakajima; Atsuko Murashima; Masahiro Hayashi
Journal:  J Obstet Gynaecol Res       Date:  2021-02-25       Impact factor: 1.730

4.  Drug use during pregnancy in Sweden - assessed by the Prescribed Drug Register and the Medical Birth Register.

Authors:  Olof Stephansson; Fredrik Granath; Tobias Svensson; Bengt Haglund; Anders Ekbom; Helle Kieler
Journal:  Clin Epidemiol       Date:  2011-02-01       Impact factor: 4.790

5.  Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan.

Authors:  Ken Nakajima; Omi Watanabe; Mayumi Mochizuki; Ayako Nakasone; Nobuhiko Ishizuka; Atsuko Murashima
Journal:  Mod Rheumatol       Date:  2016-03-04       Impact factor: 3.023

6.  Drug Use before and during Pregnancy in Japan: The Japan Environment and Children's Study.

Authors:  Hidekazu Nishigori; Taku Obara; Toshie Nishigori; Hirohito Metoki; Mami Ishikuro; Satoshi Mizuno; Kasumi Sakurai; Nozomi Tatsuta; Ichiko Nishijima; Ikuma Fujiwara; Takahiro Arima; Kunihiko Nakai; Nariyasu Mano; Shinichi Kuriyama; Nobuo Yaegashi
Journal:  Pharmacy (Basel)       Date:  2017-04-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.